A cross sectional study was planned to assess how adequately primary hypothyroid patients are being monitored on replacement therapy in our clinical setup in order to highlight the correct or incorrect routines which are followed in our clinical practice. The study was specially aimed as to what hormone(s) levels (TSH, T4, T3 singly or in combination) are being advised/used for monitoring thyroid replacement therapy in our setup. All diagnosed cases of primary hypothyroidism (n=140, 109 Females and 31 male) on thyroxine replacement therapy, reporting to Pathology Department PNS SHIFA for their thyroid profile from 1st August 2000 to 31st January 2001 were included. Detailed clinical information was recorded. TSH was used as basic tool. If T4 and/or T3 were advised in any patient that was also recorded. A total of 140 (100%) patients of primary hypothyroidism on thyroxine replacement therapy were studied including 109 female (77.86%) and 31 males (22.14%).. Medical specialists treated 101 patients (72.14%) while 39 (27.86%) were being treated by general practitioners. Disease was well controlled in 43 (30.7%) patients as TSH level was within reference range (0.4-5.0µU/ml). The under treated patients were 73 (52.14%) with high TSH (>5µU/ml) while 24 (17.14%) patients had low TSH (4 was advised for treatment monitoring. TSH alone was used as a monitoring tool in 41.4% patient while in 2.8 % cases all the three parameters (TSH, T4 and T3) were advised. The follow-up interval was mostly 6-12 months. New cases were more regular for follow-up than older patients. It is concluded that in our clinical setup there is no clear-cut strategy for treatment and its monitoring of patients with primary hypothyroidism. Medical specialists are able to achieve a better disease control than general practitioners. More education is required for adopting TSH alone as a monitoring tool.